Navigation Links
Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems
Date:8/9/2011

Supplemental Financial InformationThe following tables provide a reconciliation of our reported (GAAP) statements of operations to our adjusted statements of operations for each of the three months ended June 30, 2011 and June 30, 2010 (in thousands, except per share data): Three Months Ended June 30, 2011 (unaudited)Actual
Reported
(GAAP)AdjustmentsAdjustedREVENUES

$  607,611

$  —$  607,611COSTS AND EXPENSES: Cost of revenues

236,697

(52,018)

(1)

184,679 Selling, general and administrative

178,133

(954)

(2)

177,179 Research and development

40,840

(4,990)

(3)

35,850 Acquisition-related items

17,626

(17,626)

(4)

—OPERATING INCOME

$  134,315

$  75,588$  209,903INTEREST EXPENSE, NET

25,560

(4,719)

(5)

20,841LOSS ON EXTINGUISHMENT OF DEBT, NET

8,548

(8,548)

(6)

—OTHER INCOME, NET

(125)

—(125)INCOME BEFORE INCOME TAXES

$  100,332

$  88,855$  189,187INCOME TAXES

32,780

14,738

(7)

47,518CONSOLIDATED NET INCOME

$  67,552

$  74,117$  141,669Less: Net income attributable to noncontrolling interests

(12,969)

—(12,969)NET INCOME ATTRIBUTABLE TO ENDO PHARMACEUTICALS HOLDINGS INC.

$  54,583

74,117$  128,700DILUTED EARNINGS PER SHARE

$  0.44$  1.05DILUTED WEIGHTED AVERAGE SHARES

122,686122,686Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations:(1) To exclude amortization of commercial intangible assets related to marketed products of $40,023, the impact of inventory step-up recorded as part of acquisition accounting of $2,995, and milestone payments to partners of $9,000.

(
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 Securities lawyers ... board of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ... per share. Concerned SLXP investors are encouraged to contact ... The investigation focuses upon the shareholder value ... Salix shareholders would receive only $158.00 per share in ...
(Date:2/27/2015)... -- Boston Scientific Corporation (NYSE: BSX ) is ... Conference on March 10 in Miami Beach ... vice president and chief financial officer, and Susie ... a 25-minute question and answer session regarding the company ... Following a 5-minute break, a question and answer session ...
(Date:2/27/2015)... MISSISSAUGA, ON , Feb. 27, 2015 /CNW/ - Covalon ... advanced medical technologies company, today announced financial results for ... For the three months ended December 31, 2014, ... for the quarter was $229,820 or $0.02 per share.  ... Pedlar , said "I am very pleased with the ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... NEW YORK, Aug. 14 Immtech Pharmaceuticals,Inc. (Amex: ... paper published in Nucleic,Acids Research by a group ... ability of furamidine to inhibit a key enzyme ... Furamidine is the active metabolite (DB75),of Immtech,s proprietary, ...
... Scheduled Start of Phase 3 Clinical Trial, BELTSVILLE, ... has reported a second quarter 2007 loss from continuing,operations ... to a loss from,continuing operations of $699,000, or 5 ... from discontinued operations in the second quarter,of 2007 was ...
Cached Medicine Technology:Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3Spherix Reports Second Quarter Earnings 2
(Date:2/28/2015)... In recent years Medical Marijuana has continuously been ... a way for them to expand their patient base without ... Since the FDA still lists Cannabis as a Schedule 1 ... physicians that can help guide them when recommending a ... in Santa Cruz, CA is a leader in the small, ...
(Date:2/28/2015)... AB (PRWEB) February 28, 2015 The ... is now a distributor of the machine. The Heart ... of their license, like a franchise model. The goal ... prevent and reverse heart disease. To buy External ... Fit Clinic can help individuals through this process and ...
(Date:2/28/2015)... NB (PRWEB) February 28, 2015 ... center software suite for Asterisk, are pleased to announce ... highly successful 5.7 and 5.8 versions of Q-Suite, this ... well as a number of new features to the ... Q2 2015. , Q-Suite 5.9 will add features to ...
(Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
(Date:2/28/2015)... 28, 2015 How would you ... , There are all kinds of different leaders, ... awareness of the advantages and applications of different ... launching a new product this spring called The ... the connection between personality type, leadership, and success. ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3
... be "alarmingly dismal" with over 180 million urban poor having ... an industry analysis. ,At least 300 additional urban ... annually to cater to the needs of 215 million urban ... of Commerce and Industry of India (ASSOCHAM). ,In ...
... of colorectal cancers getting missed out in patients undergoing ... a gastroenterologist// or a surgeon. This was disclosed by ... researchers. ,This study was conducted on 12,487 ... Ontario along with her team. According to this study, ...
... flu in their county. This was disclosed by Faizullah Kakar, ... H5N1 virus was found in the eastern province of Nangarhar. ... diagnosed as the case of malaria. The Nangarhar area has ... ,Culling of birds was initiated earlier this week ...
... risk of mercury in canned albacore tuna in women and ... tuna in women and children. This follows a recent report ... cans of albacore tuna tested contained mercury more than the ... of canned albacore tuna per week can be had by ...
... and intolerance to gluten.// ,Inflammatory ... inflammations in muscular tissue. Coeliac disease is ... ,Inflammatory myopathies are inflammatory infiltrates ... includes polymyositis, dermatomyositis, and inclusion-body myositis. Little ...
... the heart gets its distinguishing shape? Shape may be formed ... and shape, all of which react to// influences from the ... bulges later on to develop into cardiac chambers. ... journal PLoS Biology, Heidi Auman, Deborah Yelon, and colleagues found, ...
Cached Medicine News:Health News:Urban Poor in Dire Need of Proper Healthcare: Report 2Health News:Inflammatory Myopathy may Indicate Intolerance to Gluten 2
Donor Screen & Confirmation Kit...
... method for Dimension integrated chemistry systems ... in vitro diagnostic test intended to ... (TPSA) in human serum or plasma. ... in the detection of prostate cancer ...
... Wampole Laboratories offers a comprehensive line of ... serum and urine in convenient one-step stick ... 2 testing options. Clearview Easy HCG is ... convenient stick format. Clearview HCG II ...
The BioCheck hCG ELISA is intended for the quantitative determination of human chorionic gonadotropin (hCG) concentration in human serum. The assay is for use in the early diagnosis of pregnancy in a...
Medicine Products: